Arca
Skip to content

Warning Letter to Valley Biosystems

Biologics. See Valley Biosystems's company page or this site's inspections.

On Oct 14, 2022, FDA's CBER sent Valley Biosystems a warning letter.

  • Letter date: Oct 14, 2022
  • Issued by: CBER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

Dear Mr. Cello:

The United States Food and Drug Administration (FDA) acknowledges receipt of your letter dated August 24, 2022, responding to the Warning Letter (WL) issued by FDA on August 3, 2022, to Valley Biosystems Inc. (VBS). The WL pertained to the firm’s conduct involving Good Laboratory Practice (GLP) nonclinical studies S18-10688 and S19-10708.

We reviewed your response stating that VBS developed a post-inspection action plan to remediate the inspectional findings and that VBS was acquired by Altasciences USA LLC (Altasciences). We acknowledge your firm’s commitment to no longer perform FDA regulated GLP nonclinical studies under 21 CFR Part 58, and note that VBS and Altasciences have taken steps to cease conducting such GLP studies for the VBS clients.

Your action has resolved the remaining issues described in the August 3, 2022, Warning Letter.

Sincerely, /S/ Melissa J. Mendoza, JD Acting Director Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research

cc: Eric Pittman, Director FDA ORA-BIMO West

The Firm's Other Letters

Same company or the same FDA site, newest first

Record

Recipient
Steve Cello
FDA site ID (FEI)
3004554935
Cited
—

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.